March 27 (Reuters) – AstraZeneca said on Friday said its experimental treatment tozorakimab met the main goal in two late-stage trials and showed a meaningful reduction in flare ups of chronic obstructive pulmonary disease, also known as “smoker’s lung”.
(Reporting by Nithyashree R B and Pushkala Aripaka in Bengaluru; Editing by Nivedita Bhattacharjee)
